Dialog Box

Combination BRAF/MEK inhibitors therapy approved for rare cancers

The Food and Drug Administration (FDA) has recently approved the combined use of the BRAF/MEK inhibitors, Dabrafenib and Trametinib, as a treatment for patients with BRAF V600E–positive solid tumours who have no suitable alternative treatment options. 

This combination treatment has demonstrated to induce an overall response rate of up to 80% in multiple rare BRAF-positive tumour types, including gliomas, biliary tract, gynaecologic, and gastrointestinal cancers. Approval of these drugs is supported by several clinical trials, such as the phase 2 ROAR trial (NCT02034110) and the NCI-MATCH (NCT02465060) Subprotocol H study.

Australian patients with BRAF V600-positive rare cancers may be eligible for clinical trials of BRAF/MEK inhibitors or similar investigational drugs on clinical trials, including MoST sub-study 12 (vemurafenib and combimetinib). The Australian Rare Cancer Portal can assist with identifying the most relevant clinical trial near you.

Learn More

To learn more about these clinical studies, please visit:

ROAR trial (The Lancet)ROAR trial (J Clin Oncol)NCI-MATCH Trial Subprotocol H (J Clin Oncol)

17 August 2022
Category: News